XML 98 R71.htm IDEA: XBRL DOCUMENT
v3.20.4

COMMITMENTS - Agreements to Purchase IP (Details) |  |  | 12 Months Ended |  |  |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Jun. 30, 2014 USD ($) | Aug. 11, 2010 USD ($) item | Dec. 31, 2014 USD ($) | Dec. 31, 2020 USD ($) | Dec. 31, 2019 USD ($) | Oct. 31, 2019 shares | Oct. 17, 2019 USD ($) shares | Dec. 31, 2018 USD ($) shares | Aug. 31, 2018 shares | Mar. 30, 2015 USD ($)
Commercialization rights |  |  |  |  |  |  |  |  |  |
Commitments |  |  |  |  |  |  |  |  |  |
Commercialization rights at fair value |  |  |  |  |  |  | $ 11,800,000 |  |  |
Australian Asset Purchase Agreement |  |  |  |  |  |  |  |  |  |
Commitments |  |  |  |  |  |  |  |  |  |
Number of therapeutic candidates | item |  | 3 |  |  |  |  |  |  |  |
Upfront initial payment per agreement |  | $ 500,000 | $ 1,000,000 |  |  |  |  |  |  |
Aggregate payments made |  |  |  | $ 1,500,000 |  |  |  |  |  |
Australian Asset Purchase Agreement | Minimum |  |  |  |  |  |  |  |  |  |
Commitments |  |  |  |  |  |  |  |  |  |
Percentage of revenues to be paid in the future |  | 7.00% |  |  |  |  |  |  |  |
Australian Asset Purchase Agreement | Maximum |  |  |  |  |  |  |  |  |  |
Commitments |  |  |  |  |  |  |  |  |  |
Percentage of revenues to be paid in the future |  | 20.00% |  |  |  |  |  |  |  |
Salix Pharmaceuticals, Ltd. Agreement |  |  |  |  |  |  |  |  |  |
Commitments |  |  |  |  |  |  |  |  |  |
Upfront initial payment per agreement |  |  | $ 7,000,000 |  |  |  |  |  |  |
German Publicly Traded Company Arrangement |  |  |  |  |  |  |  |  |  |
Commitments |  |  |  |  |  |  |  |  |  |
Upfront initial payment per agreement | $ 1,000,000 |  |  |  |  |  |  |  |  |
German Publicly Traded Company Arrangement | Maximum |  |  |  |  |  |  |  |  |  |
Commitments |  |  |  |  |  |  |  |  |  |
Royalties percentage | 30.00% |  |  |  |  |  |  |  |  |
U.S. Private Company Arrangement |  |  |  |  |  |  |  |  |  |
Commitments |  |  |  |  |  |  |  |  |  |
Milestones to be paid |  |  |  |  |  |  |  |  |  | $ 2,000,000
Non-current liability |  |  |  | 750,000 | $ 500,000 |  |  | $ 500,000 |  |
Aggregate payments made |  |  |  | $ 3,000,000 |  |  |  |  |  | 1,500,000
Cosmo Pharmaceuticals N.V. Strategic Collaboration | Cosmo Pharmaceuticals N.V. |  |  |  |  |  |  |  |  |  |
Commitments |  |  |  |  |  |  |  |  |  |
Investment in strategic collaboration |  |  |  |  |  |  | 36,300,000 |  |  |
Cosmo Pharmaceuticals N.V. Strategic Collaboration | Maximum |  |  |  |  |  |  |  |  |  |
Commitments |  |  |  |  |  |  |  |  |  |
Commitments in relation to joint ventures |  |  |  |  |  |  | $ 100,000,000 |  |  |
Revenue Milestone | U.S. Private Company Arrangement | Maximum |  |  |  |  |  |  |  |  |  |
Commitments |  |  |  |  |  |  |  |  |  |
Milestones to be paid |  |  |  |  |  |  |  |  |  | $ 2,000,000
ADSs |  |  |  |  |  |  |  |  |  |
Commitments |  |  |  |  |  |  |  |  |  |
Number of shares issued | shares |  |  |  |  |  |  |  | 2,857,143 | 4,166,667 |
Ordinary shares | Cosmo Pharmaceuticals N.V. Strategic Collaboration | Cosmo Pharmaceuticals N.V. |  |  |  |  |  |  |  |  |  |
Commitments |  |  |  |  |  |  |  |  |  |
Number of shares issued | shares |  |  |  |  |  |  | 5,185,715 |  |  |
Ordinary shares | Cosmo Pharmaceuticals N.V. Strategic Collaboration | Cosmo Technologies Ltd. |  |  |  |  |  |  |  |  |  |
Commitments |  |  |  |  |  |  |  |  |  |
Number of shares issued | shares |  |  |  |  |  |  | 1,714,286 |  |  |
Ordinary shares | ADSs | Cosmo Pharmaceuticals N.V. |  |  |  |  |  |  |  |  |  |
Commitments |  |  |  |  |  |  |  |  |  |
Number of shares issued | shares |  |  |  |  |  | 5,185,715 |  |  |  |
Ordinary shares | ADSs | Cosmo Technologies Ltd. |  |  |  |  |  |  |  |  |  |
Commitments |  |  |  |  |  |  |  |  |  |
Number of shares issued | shares |  |  |  |  |  | 1,714,286 |  |  |  |

X
- Definition The commitments that the entity has relating to its joint ventures as specified in paragraphs B18-B20 of IFRS 12. [Refer: Joint ventures [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2020-01-01 -Paragraph 23 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_23_a&doctype=Standard -URIDate 2020-01-01 + Details
Name: | ifrs-full_CommitmentsInRelationToJointVentures
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The fair value of financial assets. [Refer: At fair value [member]; Financial assets] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 7 -IssueDate 2020-01-01 -Paragraph 25 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2020-en-r&anchor=para_25&doctype=Standard -URIDate 2020-01-01 + Details
Name: | ifrs-full_FinancialAssetsAtFairValue
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of investments in joint ventures in an entity's separate financial statements. [Refer: Joint ventures [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2020-01-01 -Paragraph 10 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2020-en-r&anchor=para_10&doctype=Standard -URIDate 2020-01-01 + Details
Name: | ifrs-full_InvestmentsInJointVentures
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of non-current contract liabilities. [Refer: Contract liabilities] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2020-01-01 -Paragraph 105 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2020-en-r&anchor=para_105&doctype=Standard -URIDate 2020-01-01 + Details
Name: | ifrs-full_NoncurrentContractLiabilities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The number of shares issued by the entity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2020-01-01 -Paragraph 106 -Subparagraph d -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_106_d&doctype=Standard -URIDate 2020-01-01 + Details
Name: | ifrs-full_NumberOfSharesIssued
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Aggregate payments paid to the collaborative partner, as of the balance sheet date. + References No definition available. + Details
Name: | rdhl_AggregatePaymentsAsOfReportingPeriod
Namespace Prefix: | rdhl_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | rdhl_CollaborativeArrangementsTransactionsLineItems
Namespace Prefix: | rdhl_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Milestone payments to be paid to collaborative partner. + References No definition available. + Details
Name: | rdhl_MilestonesToBePaid
Namespace Prefix: | rdhl_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the number of therapeutic candidates. + References No definition available. + Details
Name: | rdhl_NumberOfTherapeuticCandidates
Namespace Prefix: | rdhl_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of revenues to be paid to the collaborative partner. + References No definition available. + Details
Name: | rdhl_PercentageRevenuesExpectedToBePaid
Namespace Prefix: | rdhl_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the percentage of royalties. + References No definition available. + Details
Name: | rdhl_RoyaltiesPercentage
Namespace Prefix: | rdhl_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront arrangement amount paid by the reporting entity to the collaborative partner. + References No definition available. + Details
Name: | rdhl_UpfrontInitialPaymentPerAgreement
Namespace Prefix: | rdhl_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=rdhl_CommercializationRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | rdhl_TypeOfArrangementTransactionsAxis=rdhl_AustralianAssetPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | rdhl_TypeOfArrangementTransactionsAxis=rdhl_SalixPharmaceuticalsLtd.AgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | rdhl_TypeOfArrangementTransactionsAxis=rdhl_GermanPubliclyTradedCompanyArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | rdhl_TypeOfArrangementTransactionsAxis=rdhl_U.s.PrivateCompanyArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | rdhl_TypeOfArrangementTransactionsAxis=rdhl_CosmoPharmaceuticalsN.v.StrategicCollaborationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=rdhl_CosmoPharmaceuticalsN.v.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | rdhl_MilestoneAxis=rdhl_RevenueMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ClassesOfOrdinarySharesAxis=rdhl_AmericanDepositorySharesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=rdhl_CosmoTechnologiesLtd.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |